MagniXene®
Lung Functional Imaging (COPD, Asthma, Lung Cancer)
Clinical TrialsActive
Key Facts
Indication
Lung Functional Imaging (COPD, Asthma, Lung Cancer)
Phase
Clinical Trials
Status
Active
Company
About Xemed
Xemed is a private, product-focused diagnostic company pioneering hyperpolarized xenon-129 (129Xe) MRI for pulmonary functional imaging. Its core technology platform includes the MagniXene® investigational drug and the XeBox-E10 polarizer system, which together enable visualization of lung ventilation and gas exchange. The company is in the clinical stage, collaborating with major academic centers to validate its technology for indications like COPD, asthma, and lung cancer, aiming to provide non-invasive, radiation-free diagnostic tools. Xemed operates as a pre-revenue entity, advancing its programs through research partnerships and regulatory filings.
View full company profile